Dr. Robert Mabry is Chief Scientific Officer of Averna Therapeutics, bringing deep expertise in genomic medicine research, translational strategy, and drug discovery. Prior to joining Averna, he was CEO of Hillstar Bio, where he led the company’s work in precision immunotherapy for autoimmune diseases. Previously, he served as CSO of Orna Therapeutics, where he led drug discovery and development of the company’s circular RNA therapeutics platform. Earlier in his career, he held senior leadership roles at Takeda Pharmaceuticals, Cogen Therapeutics, Jounce Therapeutics, Adimab, ZymoGenetics, and ImClone Systems.
He holds a PhD in Biochemistry from the University of Texas at Austin and a BA in Biology/Biochemistry from Baylor University.
Our Team
